Effect of class-based lifestyle intervention on the management of childhood obesity.

OBJECTIVES: Childhood obesity is prevalent in southern Taiwan and lifestyle interventions for the management of childhood obesity are challenging. How to overcome the barriers of implementation programs is crucial. We offered lunchtime education and integrated it into education programs. Finally, we evaluated whether such an intervention could change unhealthy behaviors and reduce obesity tendency among elementary students. METHODS: This was a prospective cohort study, conducted at an elementary school from September 2015 to July 2018. We distributed a lifestyle questionnaire to assess the students' dietary habits and physical activities before our intervention. We offered class-based interactive nutrition programs and record the behavior and weight change each semester. The body mass index (BMI) of the students were obtained each semester, and they were categorized as underweight, normal, overweight, and obese according to the age-specific BMI. RESULTS: In total, 279 students were followed for 3 consecutive years. The most prevalent unhealthy dietary habit was the consumption of sweetened beverages in approximately 76% of the students. At the end of the study, the percentage of normal weight increased and the overall percentage of overweight/obesity decreased in both groups. At the end of the study, the BMI-time curve became flatter than that of Kaohsiung (regional) city and approached the national standard. It indicates that the increase in average BMI was effectively delayed with our intervention. CONCLUSIONS: Lunchtime education is an innovative way to provide class-based education programs in school that yielded behavior changes and are effective approaches for delaying childhood obesity.

Prevention of Tamoxifen-related Nonalcoholic Fatty Liver Disease in Breast Cancer Patients.

BACKGROUND: Tamoxifen is commonly used to prevent breast cancer recurrence. Studies have confirmed the association between tamoxifen and nonalcoholic fatty liver disease (NAFLD), with the results indicating the need for aggressive management of this side effect. We assessed the potential risk factors for and identified the possible protective factors of tamoxifen-related fatty liver. MATERIALS AND METHODS: We enrolled patients with a history of breast cancer, aged 20 to 70 years, who had received with tamoxifen treatment within the past 5 years. We obtained the initial data and performed a follow-up blood test and ultrasound examination to compare the differences before and after tamoxifen treatment. The patients were divided into relatively normal and fatty liver groups. RESULTS: Of the 266 enrolled tamoxifen-treated patients, 143 (53.8%) and 123 (46.2%) were in the relatively normal and fatty liver groups, respectively. The initial body weight (57.6 ± 9.3 kg vs. 60.9 ± 10.3 kg; P = .006) and body mass index (BMI; 23.4 ± 3.8 kg/m2 vs. 25.0 ± 4.2 kg/m2; P < .001) were lower in the relatively normal group. An initial BMI of ≥ 22 kg/m2 was a potential risk factor for tamoxifen-related NAFLD (hazard ratio [HR], 1.58; 95% confidence interval [CI], 1.00-2.48; P = .048). In contrast, a weekly exercise duration of ≥ 150 minutes reduced the risk (HR, 0.47; 95% CI, 0.31-0.69; P < .001). CONCLUSION: The results from our study suggest that a BMI of ≥ 22 kg/m2 is a potential risk factor for tamoxifen-related fatty liver and exercise is a possible protective factor.

Differential Effects of Bariatric Surgery Versus Exercise on Excessive Visceral Fat Deposits.

The aim of the present study was to compare differential impacts of bariatric surgery and exercise-induced weight loss on excessive abdominal and cardiac fat deposition.Excessive fat accumulation around the heart may play an important role in the pathogenesis of cardiovascular disease. Recent evidences have suggested that bariatric surgery results in relatively less decrease in epicardial fat compared with abdominal visceral fat and paracardial fat.Sixty-four consecutive overweight or obese subjects were enrolled in the study. Clinical characteristics and metabolic profiles were recorded. The volumes of abdominal visceral adipose tissue (AVAT), abdominal subcutaneous adipose tissue (ASAT), epicardial (EAT), and paracardial adipose tissue (PAT) were measured by computed tomography in the bariatric surgery group (N = 25) and the exercise group (N = 39) at baseline and 3 months after intervention. Subjects in both the surgery and exercise groups showed significant reduction in body mass index (15.97%, 7.47%), AVAT (40.52%, 15.24%), ASAT (31.40, 17.34%), PAT (34.40%, 12.05%), and PAT + EAT (22.31%, 17.72%) (all P < 0.001) after intervention compared with baseline. In both the groups, the decrease in EAT was small compared with the other compartments (P < 0.01 in both groups). Compared with the exercise group, the surgery group had greater loss in abdominal and cardiac visceral adipose tissue (AVAT, ASAT, PAT, EAT+PAT) (P < 0.001), but lesser loss in EAT (P = 0.037).Compared with the exercise group, bariatric surgery results in significantly greater percentage loss of excessive fat deposits except for EAT. EAT, but not PAT, was relatively preserved despite weight reduction in both the groups. The physiological impact of persistent EAT deserves further investigation.

Association between tamoxifen treatment and the development of different stages of nonalcoholic fatty liver disease among breast cancer patients.

BACKGROUND/PURPOSE: For estrogen-receptor positive breast cancer cases, tamoxifen has been the most important adjuvant hormonal therapy for the purpose of reducing recurrence rates and prolonging disease free survival. However, several side effects have been noticed, and fatty liver is one of the most common side effects among them. Since fatty liver is a common problem in the general population, we wanted to examine the effects of tamoxifen under pre-existing fatty liver conditions and evaluate the prevalence of tamoxifen-related impaired liver function. METHODS: We recruited breast cancer cases at ages 20-70 years and divided them into tamoxifen or control groups. Personal information was collected, and fasting blood tests and abdominal ultrasound were performed. The changes of fatty liver degree between the initial and follow-up ultrasound were divided into five categories. RESULTS: Of the 406 enrolled participants, 266 were in the tamoxifen group and 140 were in the control group. The tamoxifen group had a higher risk of newly developed fatty liver [hazard ratio (HR) = 3.69; 95% confidence interval (CI) 1.67-8.13), lower rate of improved fatty liver (HR = 0.33; 95% CI 0.15-0.75), and higher rate of worsened fatty liver (HR = 2.11; 95% CI 1.02-4.35). CONCLUSION: The current study suggests that tamoxifen treatment is associated with the risk of fatty liver either by increasing the risk of newly developed fatty liver conditions or worsening previous fatty liver conditions, and even retarding fatty liver improvement.

The benefits of body weight loss on health-related quality of life.

BACKGROUND: Obesity is a worldwide public health issue, and the prevalence of obesity is also increasing steadily in Taiwan. Obesity leads to several chronic diseases. Often, impaired quality of life is a consequence of obesity. The aim of this study was to determine if body weight-loss could improve health-related quality of life (HRQOL) in Taiwan. METHODS: The cutoff for obesity is body mass index (BMI) = 27 as compared with 30 in US and Europe. We enrolled 67 participants with BMI ≥ 27 and more than one criterion of the metabolic syndrome, who underwent 3 months of body weight-loss intervention by diet control and regular exercise. We performed anthropometric measurements and blood tests, and administered the WHOQOL-BREF questionnaire Taiwanese version to assess HRQOL before and after the weight loss intervention. This is the first study using the WHOQOL-BREF to examine HRQOL in Taiwan. The questionnaire included D1 physical, D2 psychological, D3 social relationships and D4 environmental domains; each was scored from 4 to 20. RESULTS: Obese subjects had lower D1 and D2 scores as compared with the Taiwan healthy population reference group at baseline. In this study, 38 participants completed the 3-month intervention program and 29 participants dropped out. Twenty-five participants reached the 5% of initial BMI goal. Among them, significant statistical improvements were found both in medical comorbidities and in the four domains of the HRQOL questionnaire. CONCLUSION: Obesity can cause impaired HRQOL, which can be improved through BMI intervention. In addition to the benefits of biomedical aspect, this could be an incentive goal for keeping body weight control.